|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
159,210,000 |
Market
Cap: |
1.34(B) |
Last
Volume: |
2,204,422 |
Avg
Vol: |
2,183,785 |
52
Week Range: |
$3.36 - $8.83 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drugs - Generic |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 346 |
Guru Rank Value : 6 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Amneal Pharmaceuticals is a holding company. Through its subsidiaries, Co. is a pharmaceutical company engaging in developing, manufacturing, marketing and distributing generic and branded pharmaceutical products across an array of dosage forms and therapeutic areas. Co. has three reportable segments: Generics, which includes various product families covering a range of dosage forms and delivery systems; Specialty, which is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products, with a focus on products addressing central nervous system disorders; and AvKARE, which provides pharmaceuticals, medical and surgical products, and services.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Nestor Michael |
President, Impax Pharm. |
|
2016-05-23 |
4 |
D |
$32.12 |
$54,476 |
D/D |
(1,696) |
123,096 |
|
- |
|
Benet Leslie Z |
Director |
|
2016-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
4,375 |
20,225 |
|
- |
|
Burr Robert L |
Director |
|
2016-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
4,375 |
56,100 |
|
- |
|
Chao Allen |
Director |
|
2016-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
4,375 |
65,070 |
|
- |
|
Terreri Peter R |
Director |
|
2016-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
4,375 |
44,162 |
|
- |
|
Pendergast Mary K |
Director |
|
2016-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
4,375 |
17,975 |
|
- |
|
Vergis Janet S. |
Director |
|
2016-05-17 |
4 |
A |
$0.00 |
$0 |
D/D |
4,375 |
7,775 |
|
- |
|
Schlossberg Mark A |
SVP and General Counsel |
|
2016-05-15 |
4 |
D |
$29.18 |
$67,989 |
D/D |
(2,330) |
89,016 |
|
- |
|
Nestor Michael |
President, Impax Pharm. |
|
2016-05-15 |
4 |
D |
$29.18 |
$94,426 |
D/D |
(3,236) |
124,792 |
|
- |
|
Reasons Bryan M. |
Chief Financial Officer |
|
2016-05-15 |
4 |
D |
$29.18 |
$35,483 |
D/D |
(1,216) |
88,705 |
|
- |
|
Schlossberg Mark A |
SVP and General Counsel |
|
2016-05-14 |
4 |
D |
$29.18 |
$63,116 |
D/D |
(2,163) |
91,346 |
|
- |
|
Nestor Michael |
President, Impax Pharm. |
|
2016-05-14 |
4 |
D |
$29.18 |
$87,628 |
D/D |
(3,003) |
128,028 |
|
- |
|
Reasons Bryan M. |
Chief Financial Officer |
|
2016-05-14 |
4 |
D |
$29.18 |
$55,121 |
D/D |
(1,889) |
89,921 |
|
- |
|
Nornhold Jeffrey |
SVP, Technical Operations |
|
2016-05-14 |
4 |
D |
$29.18 |
$9,834 |
D/D |
(337) |
79,976 |
|
- |
|
Wilkinson George Fred |
Chief Executive Officer |
|
2016-04-29 |
4/A |
D |
$33.35 |
$3,242,254 |
D/D |
(97,219) |
429,237 |
|
- |
|
Wilkinson George Fred |
Chief Executive Officer |
|
2016-04-29 |
4 |
D |
$33.35 |
$2,054,160 |
D/D |
(61,594) |
464,862 |
|
- |
|
Reasons Bryan M. |
Chief Financial Officer |
|
2016-04-13 |
4 |
D |
$35.35 |
$36,587 |
D/D |
(1,035) |
91,810 |
|
- |
|
Benet Leslie Z |
Director |
|
2016-03-14 |
4 |
OE |
$6.55 |
$22,925 |
D/D |
3,500 |
15,850 |
|
- |
|
Schlossberg Mark A |
SVP and General Counsel |
|
2016-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
21,852 |
93,509 |
|
- |
|
Schlossberg Mark A |
SVP and General Counsel |
|
2016-02-26 |
4 |
D |
$33.27 |
$64,244 |
D/D |
(1,931) |
71,657 |
|
- |
|
Nestor Michael |
President, Impax Pharm. |
|
2016-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
21,852 |
131,031 |
|
- |
|
Nestor Michael |
President, Impax Pharm. |
|
2016-02-26 |
4 |
D |
$33.27 |
$88,299 |
D/D |
(2,654) |
109,179 |
|
- |
|
Nornhold Jeffrey |
SVP, Technical Operations |
|
2016-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
17,317 |
80,313 |
|
- |
|
Nornhold Jeffrey |
SVP, Technical Operations |
|
2016-02-26 |
4 |
D |
$33.27 |
$40,057 |
D/D |
(1,204) |
62,996 |
|
- |
|
Reasons Bryan M. |
Chief Financial Officer |
|
2016-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
26,113 |
92,845 |
|
- |
|
180 Records found
|
|
Page 4 of 8 |
|
|